Antibody against fibroblast growth factor-23
CA 2471656 C · Owner: Yamashita, Takeyoshi · Inventors: Yamashita, Takeyoshi; Yamazaki, Yuji; Shimada, Takashi
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The purpose of the present invention is to provide an antibody against fibroblast growth factor 23. The antibody is obtained by immunizing an animal with a polypeptide which comprises an amino acid sequence represented by SEQ ID NO: 1, or an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO: 1 by deletion substitution, or addition of 1 or , several amino acids, and has fibroblast growth factor-23 activity and activity to control phosphate metabolism or vitamin D metabolism and is shown by the , following (a), (b) or (c):, (a) an antibody, which recognizes an amino acid sequence between the 180th and the 194th, or the 237th and the 251st amino acid …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 6, 2003 and granted July 31, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended January 6, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 6, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.